NDR contributed to the work that was published by Dr. Adriano Chaves-Filho and the Dr. Sayuri Miyamoto team. To profile oxylipins in amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, scientists from RIDC Redoxoma led by researcher Dr. Sayuri Miyamoto from the Institutode Química at Universidade de São Paulo (USP), established and validated an ultra-high performance liquid chromatography coupled to high resolution mass spectrometry (LC-HRMS) method for simultaneous analysis of 126 oxylipins in plasma. With this tool, they analyzed the plasma of an animal model of ALS and found altered oxylipins in symptomatic animals that reflect oxidative stress, inflammation, and lipid hypermetabolism. According to the researchers,oxylipins can become biomarkers for monitoring disease progression. The article Plasma oxylipin profiling by high resolution mass spectrometry reveal signatures of inflammation and hypermetabolism in amyotrophic lateral sclerosis, by Adriano B. Chaves-Filho, Larissa S. Diniz, Rosangela S. Santos, Rodrigo S. Lima, Hector Oreliana, IsabellaF.D. Pinto, Lucas S. Dantas, Alex Inague, Rodrigo L. Faria,Marisa H.G. Medeiros, IsaíasGlezer, William T. Festuccia, Marcos Y. Yoshinaga and Sayuri Miyamoto, can be accessed here
top of page
Recent Posts
See AllNeurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS. You can read about the trial and follow our progress .
22
Indiana University researcher Chandler Walker, Ph.D., developed a stem cell-based secretome therapy that influences both the central and peripheral components of Amyotrophic Lateral Sclerosis (ALS) pa
27
The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R Borchelt (Department of Neuroscience, University of Florida, Colle
31
bottom of page